- Home
- TDC vs VCRE Comparison
TDC vs VCRE Comparison
Compare TDC & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TDC | VCRE |
|---|---|---|
| Founded | 1979 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.3B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | TDC | VCRE |
|---|---|---|
| Price | $29.20 | $11.28 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $34.78 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 2.8K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.38 | N/A |
| EPS | ★ 3.47 | N/A |
| Revenue | ★ $2,156,000,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $1.44 | N/A |
| P/E Ratio | $8.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.83 | $11.00 |
| 52 Week High | $41.78 | $12.85 |
Technical Indicators
Market Signals| Indicator | TDC | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 39.78 | 22.49 |
| Support Level | $29.21 | $11.00 |
| Resistance Level | $32.03 | $12.85 |
| Average True Range (ATR) | 1.56 | 0.51 |
| MACD | -0.39 | -0.11 |
| Stochastic Oscillator | 28.71 | 15.13 |
Price Performance
Historical ComparisonAbout TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.